(untitled) - Updated survival, quality of life (QOL),
and safety data of radium-223 chloride (RA-223) in patients with castrationresistant prostate cancer (CRPC) with bone metastases from the phase 3 double-blind, randomized, multinational study (ALSYMPCA). ResearchGate Available from: [cited 2019 Feb 11]